- 1
- 2 3

# Development and validation of risk prediction tools for pressure injury occurrence: An umbrella review

5 6

4

- 7 Bethany Hillier<sup>1,2</sup>
- 8 Katie Scandrett<sup>1,2</sup>
- 9 April Coombe<sup>1,2</sup>
- 10 Tina Hernandez-Boussard<sup>3</sup>
- 11 Ewout Steyerberg<sup>4</sup>
- 12 Yemisi Takwoingi<sup>1,2</sup>
- 13 Vladica Velickovic<sup>5,6</sup>
- 14 Jacqueline Dinnes<sup>1,2\*</sup>
- 15

#### 16

#### 17 Affiliations

- 18 <sup>1</sup> Biostatistics, Evidence Synthesis, Test Evaluation And Prediction Modelling (BESTEAM), Institute of
- 19 Applied Health Research, University of Birmingham, Edgbaston, Birmingham, UK
- 20 <sup>2</sup> NIHR Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS Foundation
- 21 Trust and University of Birmingham, Birmingham, UK
- 22 <sup>3</sup> Department of Medicine, Stanford University, Stanford, CA USA
- <sup>4</sup> Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, The
   Netherlands
- <sup>5</sup> Evidence Generation Department, HARTMANN GROUP, Heidenheim, Germany
- <sup>6</sup> Institute of Public Health, Medical, Decision Making and Health Technology Assessment, UMIT, Hall,
- 27 Tirol, Austria

#### 28 Email addresses

- 29 b.hillier@bham.ac.uk (BH); k.e.scandrett@bham.ac.uk (KS); a.r.coombe@bham.ac.uk (AC);
- 30 boussard@stanford.edu (THB); e.w.steyerberg@lumc.nl (ES); y.takwoingi@bham.ac.uk (YT);
- 31 vladica.velickovic@hartmann.info (VV)
- 32 \* Corresponding author: j.dinnes@bham.ac.uk (JD)

#### 33 Keywords

34 Development, internal, external validation, prediction, prognostic, pressure injury, ulcer, overview

# 35 ABSTRACT

#### 36 Background

- 37 Pressure injuries (PIs) place a substantial burden on healthcare systems worldwide. Risk stratification
- 38 of those who are at risk of developing PIs allows preventive interventions to be focused on patients
- 39 who are at the highest risk. The considerable number of risk assessment scales and prediction
- 40 models available underscore the need for a thorough evaluation of their development, validation and
- 41 clinical utility.
- 42 Our objectives were to identify and describe available risk prediction tools for PI occurrence, their
- 43 content and development and validation methods used.

#### 44 Methods

- 45 The umbrella review was conducted according to Cochrane guidance. MEDLINE, Embase, CINAHL,
- 46 EPISTEMONIKOS, Google Scholar and reference lists were searched to identify relevant systematic
- 47 reviews. Risk of bias was assessed using adapted AMSTAR-2 criteria. Results were described
- 48 narratively. All included reviews contributed to build a comprehensive list of risk prediction tools.

#### 49 Results

- 50 We identified five systematic reviews describing the development and validation of risk prediction
- 51 tools for pressure injuries, 16 that assessed the prognostic accuracy of the tools and 10 that assessed
- 52 the clinical effectiveness. Of the five reviews of model development and validation, four included
- 53 only machine learning models. One review included detail about external validation, and this was the
- 54 only review to include model performance metrics. Where quality assessment was completed (3 out
- of 5 reviews), most prediction tools were assessed by review authors as being at high risk of bias and
- 56 no tools were assessed as being at low risk of bias.

#### 57 Conclusions

- 58 Available tools do not meet current standards for the development or reporting of risk prediction
- 59 models. The majority of tools have not been externally validated. Standardised and rigorous
- 60 approaches to risk prediction model development and validation are needed.

#### 61 Registration

- 62 The protocol was registered on the Open Science Framework (<u>https://osf.io/tepyk</u>).
- 63

64

# 65 INTRODUCTION

- 66 Pressure injuries (PI) carry a significant healthcare burden. A recent meta-analysis estimated the
- 67 global burden of PIs to be 13%, two-thirds of which are hospital-acquired PIs (HAPI).<sup>1</sup> The average
- 68 cost of a HAPI has been estimated as \$11k per patient, totalling at least \$27 billion a year in the
- 69 United States based on 2.5 million reported cases.<sup>2</sup> Length of hospital stay is a large contributing
- cost, with patients over the age of 75 who develop HAPI having on average a 10-day longer hospital
- 71 stay compared to those without PI.<sup>3</sup>
- 72 PIs result from prolonged pressure, typically on bony areas like heels, ankles, and the coccyx, and are
- 73 more common in those with limited mobility, including those who are bedridden or wheelchair
- vul rate of the setting of the setti
- 75 Multicomponent preventive strategies are needed to reduce PI incidence<sup>4</sup> with timely
- <sup>76</sup> implementation to both reduce harm and burden to healthcare systems.<sup>5</sup> Where preventive
- 77 measures fail or are not introduced in adequate time, PI treatment involves cleansing, debridement,
- topical and biophysical agents, biofilms, growth factors and dressings<sup>678</sup>, and in severe cases, surgery
- 79 may be necessary.<sup>59</sup>
- 80 A number of clinical assessment scales for assessing the risk of PI are available (e.g. Braden<sup>1011</sup>,
- 81 Norton<sup>12</sup>, Waterlow<sup>13</sup>) but are limited by reliance on subjective clinical judgment. Statistical risk
- 82 prediction models may offer improved accuracy over clinical assessment scales, however appropriate
- 83 methods of development and validation are required.<sup>14 15 16</sup> Although methods for developing risk
- 84 prediction models have developed considerably,<sup>14 15 17 18</sup> methodological standards of available
- 85 models have been shown to remain relatively low.<sup>17 19-22</sup> Machine learning (ML) algorithms to
- 86 develop prediction models are increasingly commonplace, but these models are at similarly high risk
- of bias<sup>23</sup> and do not necessarily offer any model performance benefit over the use of statistical
- 88 methods such as logistic regression.<sup>24</sup> Methods for systematic reviews of risk prediction model
- 89 studies have also improved,<sup>25-27</sup> with tools such as PROBAST (Prediction model Risk of Bias
- 90 Assessment Tool)<sup>28</sup> now available to allow critical evaluation of study methods.
- 91 Although several systematic reviews of PI risk assessment scales and risk prediction models for PI
- 92 (subsequently referred to as risk prediction tools) are available<sup>29-38</sup>, these have been demonstrated to
- 93 frequently focus on single or small numbers of scales or models, use variable review methods and
- 94 show a lack of consensus about the accuracy and clinical effectiveness of available tools.<sup>39</sup> We
- 95 conducted an umbrella review of systematic reviews of risk prediction tools for PI to gain further
- 96 insight into the methods used for tool development and validation, and to summarise the content of
- 97 available tools.

## 98 METHODS

- 99 Protocol registration and reporting of findings
- 100 We followed guidance for conducting umbrella reviews provided in the Cochrane Handbook for
- 101 Intervention Reviews.<sup>40</sup> The review was reported in accordance with guidelines for Preferred
- 102 Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)<sup>41</sup> (see Appendix 1), adapted for
- 103 risk prediction model reviews as required. The protocol was registered on the Open Science
- 104 Framework (<u>https://osf.io/tepyk</u>).

#### 105 Literature search

- 106 A single sensitive search strategy, developed and tested by an experienced information specialist
- 107 (AC), was conducted in January 2023. Electronic searches of MEDLINE and Embase via Ovid and

- 108 CINAHL Plus EBSCO were conducted, employing well-established systematic review and prognostic
- search filters<sup>42-44</sup> combined with specific keyword and controlled vocabulary terms relating to PI
- appropriate to each source, without restrictions on publication year. Additional simplified searches
- 111 were undertaken in EPISTEMONIKOS and Google Scholar due to the more limited search functionality
- of these two sources. The reference lists of all publications reporting reviews of prediction tools
- 113 (systematic or non-systematic) were reviewed to identify additional eligible systematic reviews and
- to populate a list of PI risk prediction tools. Title and abstract screening and full text screening were
- conducted independently and in duplicate by two of four reviewers (BH, JD, YT, KS). Any
- disagreements were resolved by discussion or referral to a third reviewer.

### 117 Eligibility criteria for this umbrella review

- 118 Published English-language systematic reviews of risk prediction models developed for adult patients
- at risk of PI in any setting were included. Reviews of clinical risk assessment tools or models
- 120 developed using statistical or ML methods were included, both with or without internal or external
- 121 validation. The use of any PI classification system<sup>6 45-47</sup> as a reference standard was eligible. Reviews
- 122 of the diagnosis or staging of those with suspected or existing PIs or chronic wounds, reviews of
- 123 prognostic factor and predictor finding studies, and models exclusively using pressure sensor data
- were excluded.
- 125 Systematic reviews were required to report a comprehensive search of at least two electronic
- databases, and at least one other indicator of systematic methods (i.e. explicit eligibility criteria,
- 127 formal quality assessment of included studies, sufficient data presented to allow results to be
- 128 reproduced, or review stages (e.g. search screening) conducted independently in duplicate.
- 129 Data extraction and quality assessment
- 130 Data extraction forms (Appendix 3) were developed using the CHARMS checklist (CHecklist for critical
- 131 Appraisal and data extraction for systematic Reviews of prediction Modelling Studies) and Cochrane
- 132 Prognosis group template.<sup>48 49</sup> One reviewer extracted data concerning: review characteristics, model
- details, number of studies and participants, study quality and results. Extractions were
- 134 independently checked by a second reviewer. Where discrepancies in model or primary study details
- 135 were noted between reviews, we accessed the primary model development publications where
- 136 possible.
- 137 The methodological quality of included systematic reviews was assessed using AMSTAR-2 (A
- 138 Measurement Tool to Assess Systematic Reviews)<sup>50</sup>, adapted for systematic reviews of risk prediction
- 139 models (Appendix 4). Quality assessment and data extraction were conducted by one reviewer and
- 140 checked by a second (BH, JD, KS), with disagreements resolved by consensus. Our adapted AMSTAR-2
- 141 contains six critical items, and limitations in any of these items reduces the overall validity of a
- 142 review.<sup>50</sup>

#### 143 Synthesis methods

- 144 Reviews were considered according to whether any information concerning model development and
- 145 validation were reported. Available data were tabulated and a narrative synthesis provided. All risk
- 146 prediction models identified are listed in Appendix 5 Table S4, including those for which no
- 147 information about model development or validation was provided at systematic review level. Where
- 148 possible, the predictors included in the tools were extracted at review level and categorised into
- 149 relevant groups in order to describe the candidate predictors associated with risk of PI. No statistical
- 150 synthesis of systematic review results was conducted. Reviews reporting results as prognostic
- accuracy (i.e. risk classification according to a binary decision) or clinical effectiveness (i.e. impact on
- 152 patient management and outcomes) are reported elsewhere.<sup>39</sup>

# 153 RESULTS

### 154 Characteristics of included reviews

155 Following de-duplication of search results, 6301 unique records remained, of which 110 were

selected for full text assessment. We obtained the full text of 104 publications of which 28 met all

157 eligibility criteria for inclusion (see Figure 1). Five reviews reported details about model development

and internal validation<sup>36 37 51-53</sup>, one of which also considered external validation<sup>52</sup>; 16 reported

accuracy data<sup>29 31-35 38 54-62</sup>; and 10 reported clinical effectiveness data.<sup>30 54 56 59 63-68</sup> Three reviews

160 reported both accuracy and effectiveness data.<sup>54 56 59</sup>

- 161 Table 1 provides a summary of systematic review methods for all 28 reviews according to whether or
- 162 not they reported any tool development methods (see Appendix 5 for full details). The five reviews
- 163 reporting prediction tool development and validation were all published within the last five years
- 164 (2019 to 2023) compared to reviews focused on the clinical utility of available tools (published from
- 165 2006 to 2022). Reviews about tool development focused primarily on ML-based models (one<sup>58</sup> of the
- 166 five reviews limited inclusion to empirically derived models including ML-based models, and four
- 167 (80%) considered only ML models) and frequently did not report study eligibility criteria related
- study participants or setting. Only one review (4%) concerning the clinical utility of models included
   ML-based models,<sup>38</sup> but more often restricted study inclusion by population or setting: hospital

169 ML-based models,<sup>38</sup> but more often restricted study inclusion by population or setting: hospital 170 inpatients (ward or acute unit) (n = 4),<sup>33 38 63 67</sup> acute settings (n=5),<sup>34 59 61 62 66</sup> or surgical patients

171  $(n=1)^{31}$ , or studies in long-term care settings  $(n=2)^{29}$  or the elderly  $(n=1)^{58}$ 

172 On average reviews about tool development included more studies than reviews of clinical utility

- 173 (median 22 compared to 13), more participants (median 234,105 compared to 6,106) and covered
- more prediction tools (median 21 compared to 3) (Table 1). Eight reviews (35%) about clinical utility
- 175 included only one risk assessment scale, whereas reviews of tool development included at least 3
- 176 different risk prediction models. The PROBAST tool for quality assessment of prediction model
- 177 studies was used in 60% (n=3) of tool development reviews<sup>37 52 53</sup> compared to none of the reviews of
- 178 clinical utility, however the remaining two reviews of tool development did not report any quality
- assessment of included studies (2 (40%) compared to 4 (17%) of reviews of clinical utility). Meta-
- 180 analysis was conducted in one of five (20%) reviews of tool development compared to more than
- half of reviews of clinical utility (13, 57%).

## 182 Methodological quality of included reviews

183 The quality of included reviews was generally low (Figure 2; Appendix 5 for detailed assessments).

184 The majority of reviews (all five reviews about tool development and 70% (16/23) reviews of clinical

- utility) partially met the AMSTAR-2 criteria for the literature search (i.e. searched two databases,
- 186 reported search strategy or key words, and justified language restrictions if used), with only two
- 187 (both reviews of clinical utility) meeting all criteria for 'Yes' (i.e. searching grey literature and
- 188 reference lists, with the search conducted within 2 years of publication). Nineteen reviews (68%)
- 189 conducted study selection in duplicate (4/5 (80%) of review about tool development and 15/23
- 190 (65%) of clinical utility reviews). Conflicts of interest were reported in all five tool development
- 191 reviews and 74% of clinical utility reviews (17/23). Reviews scored poorly on the remaining AMSTAR-
- 192 2 items, with at most half of reviews meeting the stipulated AMSTAR-2 criteria. Seven reviews (25%)
- 193 used an appropriate method of quality assessment of included studies and provided itemisation of
- 194 judgements per study. No review scored 'Yes' for all AMSTAR-2 items in either category.

195 Figure 1. PRISMA<sup>41</sup> flowchart: identification, screening and selection process



196 List of full-text articles excluded, with reasons, is given in Appendix 5.

#### 197 Table 1. Summary of included systematic review characteristics

Review characteristics	Reviews on model development and validation (N=5)	Reviews on accuracy or clinical effectiveness (N=23)	All included reviews (N=28)	
Median (range) year of publication	2021 (2019 – 2023)	2016 (2006 – 2022)	2018 (2006 – 2023)	
Eligibility criteria				
Participants				
Adults only	0 (0)	13 (57) ^	13 (46) ^	
Any age	0 (0)	3 (13)	3 (11)	
No age restriction reported	5 (100)	7 (30)	12 (43)	
Presence of PI at baseline				
No PIs at baseline	0 (0)	6 (26)	6 (21)	
NS	5 (100)	17 (74)	22 (79)	
Setting				
Any healthcare setting	0 (0)	10 (43)	10 (36)	
Hospital	1 (20)	4 (22)	5 (18)	
Long-term care	0 (0)	2 (9)	2 (7)	
Acute care (incl. surgical and ICU)	0 (0)	6 (26)	6 (21)	
Long-term, acute or community settings	0 (0)	1 (4)	1 (4)	
NS	4 (80)	0 (0)	4 (14)	
Risk assessment tools				
ML-based prediction models	4 (80)	1 (4)	5 (18)	
ML or statistical models	1 (20)	0 (0)	1 (4)	
Any prediction tool or scale	0 (0)	9 (39)	9 (32)	
Specified clinical scale(s)	0 (0)	10 (43)	10 (36)	
PI prevention strategies	0 (0)	1 (4)	1 (4)	
NS	0 (0)	2 (9)	2 (7)	
PI classification system				
Any	0 (0)	1 (4)	1 (4)	
Accepted standard classifications	0 (0)	2 (9)	2 (7)	
Several specified classification systems (NPUAP, EPUAP, AHCPR or TDCPS)	0 (0)	3 (13)	3 (11)	
Other	0 (0)	1 (4)	1 (4)	
NS	5 (100)	16 (70)	21 (75)	
Source of data				
Prospective only	0 (0)	4.5 (20) <sup>B</sup>	4.5 (16) <sup>B</sup>	
Prospective or retrospective	1 (20)	2.5 (11) <sup>B</sup>	3.5 (13) <sup>B</sup>	
NS	4 (80)	16 (70)	20 (71)	
Study design restrictions				
Yes	1 (20)	12 (52)	13 (46)	
No	0 (0)	3 (13)	3 (11)	
NS	4 (80)	8 (39)	12 (43)	
Review methods				
Median (range) no. sources <sup>c</sup> searched	5 (2 – 8)	6 (2 – 14)	5 (2 – 14)	
Publication restrictions:			, , , , , , , , , , , , , , , , , , ,	
End date (year)				
2000-2009	0 (0)	3 (13)	3 (11)	
2010-2019	1 (20)	16 (70)	17 (61)	
2020-2023	4 (80)	4 (17)	8 (29)	
Language				
English only	4 (80)	9 (39)	13 (46)	
2 languages	0 (0)	2 (9)	2 (7)	
>2 languages	0 (0)	3 (13)	3 (11)	
No restrictions	0 (0)	4 (17)	4 (14)	
NS	1 (20)	5 (22)	6 (21)	

Quality assessment tool D			
PROBAST	3 (60)	0 (0) <sup>E</sup>	3 (11) <sup>E</sup>
QUADAS	0 (0)	2 (9)	2 (7)
QUADAS-2	0 (0)	7 (30)	7 (25)
JBI tools	0 (0)	3 (13)	3 (11)
CASP	0 (0)	2 (9)	2 (7)
Other	0 (0)	6 (26)	6 (21)
None	2 (40)	4 (17)	6 (21)
Meta-analysis included	1 (20)	13 (57)	14 (50)
Method of meta-analysis			
(% of reviews incl. meta-analysis)			
Univariate RE/FE model (depending on	1 (100) <sup>F</sup>	2 (15) <sup>F</sup>	3 (21)
heterogeneity assessment)			
Univariate RE model	0 (0)	5 (38) <sup>F</sup>	5 (36) <sup>F</sup>
Hierarchical model (for DTA studies)	0 (0)	2 (15)	2 (14)
Unclear/NS	0 (0)	4 (31) <sup>F</sup>	4 (29) <sup>F</sup>
Volume of evidence			
Median (range) no. studies	22 (3 – 35)	13 (1 – 70)	16 (1 – 70)
Median (range) no. participants	234105 (6674 – 1278148)	6106 (528 – 221541)	10044 (528 – 1278148)
Median (range) no. tools	21 (3 – 35)	3 (1 – 28)	4 (1 – 35)

Figures are number (%) of reviews, unless otherwise specified. <sup>A</sup> one review<sup>58</sup> restricted to aged >60 years; <sup>B</sup> one review <sup>54</sup> states either prospective or retrospective data eligible for Research Question 1, but prospective only for Research Question

states either prospective or retrospective data eligible for Research Question 1, but prospective only for Research Question
 2, hence 0.5 added to each category; <sup>c</sup> including databases, bibliographies or registries; <sup>D</sup> reviews may fall into multiple

201 categories, therefore total number within domain not necessarily equal to N (100%); <sup>E</sup> one review<sup>38</sup> reported use of

202 PROBAST in methods, but did not present any PROBAST results; <sup>F</sup> one review conducts univariate meta-analysis for a single

estimate, e.g. c-statistic<sup>52</sup>, AUC<sup>60</sup>, RR<sup>55</sup>, or OR.<sup>56</sup>

204 AHCPR – Agency for Health Care Policy and Research; CASP – Critical Appraisal Skills Programme; DTA – diagnostic test

205 accuracy; EPUAP – European Pressure Ulcer Advisory Panel; FE – fixed effects; ICU – intensive care unit; JBI – Joanna Briggs

206 Institute; ML – machine learning; NPUAP – National Pressure Ulcer Advisory Panel; NS – not stated; PI – pressure injury;

207 PROBAST – Prediction model Risk of Bias Assessment; QUADAS (2) – Quality Assessment of Diagnostic Accuracy Studies

208 (Version 2); RE – random effects; TDCPS – Torrance Developmental Classification of Pressure Sore.

#### 209 Figure 2. Summary of AMSTAR-2 assessment results

	Re	eviews a	reporting ind/or val	model dev idation (n=	velopme :5)	nt		Review: and/o	s reporting or clinical ef	prognosti fectivene	ic accuracy ss (n=23)	'
ITEM 1 Research question	1			4				6		17		
ITEM 2 Protocol	1			4				6	1	1	16	
ITEM 3 Inclusions	1			4			2			21		
ITEM 4 Search strategy				5			2		17			4
ITEM 5 Study selection			4			1			15		8	
ITEM 6 Data extraction		2		3	}			1	.2		11	
ITEM 7 Exclusions				5			2			21		
ITEM 8 Study descriptions	1			4				10		3	10	
ITEM 9 RoB/QA		2		1	2			4	7		12	
ITEM 10 Funding of incl. studies				5			2			21		
ITEM 11 Statistical synthesis	1			4				4	10		9	
ITEM 12 RoB – impact on synthesis	1			4				4	10		9	
ITEM 13 RoB – impact on results	1			4					13		10	
ITEM 14 Heterogeneity	1			4					14		9	
ITEM 15 Conflicts of interest				5					17		6	
	0%	20%	40%	60%	80%	100%	0%	20%	40%	60%	80%	100'
			Yes	Partial Yes	N	0	N/A					

AMSTAR – A MeaSurement Tool to Assess systematic Reviews; Item 1 – Adequate research question/ inclusion criteria?; Item 2 – Protocol and justifications for deviations?; Item 3 – Reasons for study design inclusions?; Item 4 – Comprehensive search strategy?; Item 5 – Study selection in duplicate?; Item 6 – Data extraction in duplicate?; Item 7 – Excluded studies list (with

212 justifications)?; Item 8 – Included studies description adequate?; Item 9 – Assessment of RoB/quality satisfactory?; Item 10 – Studies' sources of funding reported?; Item 11 – Appropriate

213 statistical synthesis method?; Item 12 – Assessment of impact of RoB on synthesised results?; Item 13 – Assessment of impact of RoB on review results?; Item 14 – Discussion/investigation of

heterogeneity?; Item 15 – Conflicts of interest reported?; N/A – not applicable; RoB – risk of bias; QA – quality assessment. Further details on AMSTAR items are given in Appendix 4, and

results per review are given in Appendix 5. Note that where AMSTAR-2 assessment was applied to overlapping reviews (n=3) for prognostic accuracy and clinical effectiveness separately, and

resulted in differing judgements for each review question, the judgements for the prognostic accuracy review question are displayed here for simplicity.

DEV/ VAL (no. studies)	Setting of included studies; data sources	Model development algorithms	Internal validation method	Brief description of study quality	Summary of model performance results
DEV (34); unclear (1) <sup>A</sup>	HAPI/CAPI n=32; SRPI n=2; detection of PI (effect on length of stay) n=1; nursing home residents n=2	LR n=20; RF n=18; DT n=12; SVM n=12; MLP n=9; KNN n=4; LDA n=1; other n=19	CV n=10; split sample n=10; split sample and CV n=8; NS=7	No RoB assessment	N/A
DEV (9)	ICU n=3; operating room n=2; acute care hospital n=1; oncology department n=1; end- of-life care n=1; mobility-related disabilities n=1 EHRs used in all models	DT n=5; LR n=3; SVM n=2; NN n=2; RF n=1; MTS n=1; BN n=1; gradient boosting n=1	Split sample n=4; NS n=9	RoB assessed using PROBAST. Overall RoB high for all predictive models. All models at high RoB in analysis domain.	F-score ranged between 0.377 (ML Su MTS) and 0.670 (ML Su LR); g-means ranged between 0.628 (ML Kaewprag BN) and 0.822 (ML Su MTS); sensitivity ranged between 0.478 (ML Kawprag) and 0.848 (ML Yang); specificity ranged between 0.703 (ML Deng) and 0.988 (ML Su LR)
DEV (3)	SRPI cardiovascular n=2; SRPI critical care n=1 EHRs used in n=2 models	ANN n=1; XGBoost n=1; RF n=1	Split sample n=2; NS n=1	No RoB assessment	N/A
DEV (21); VAL (7)	DEV General acute care hospital n=7; long-term care n=5; specific acute care (e.g. ICU) n=4; cardiovascular surgery n=2; trauma and burn centres n=1; rehabilitation units n=1; unclear n=1 Prospective n=10; retrospective n=11 VAL Long-term care n=3; specific acute care (e.g. ICU) n=2; general (acute care) hospital n=2	LR n=16; cox regression n=5; ANN n=1; DT n=1; discriminant analysis n=1; C4.5 machine learning (DT induction algorithm) n=1; NS n=1	CV n=1; tree- pruning n=1; split sample n=1; re- sampling n=2; NS n=16	RoB assessed using PROBAST. <i>DEV</i> Overall RoB unclear for two models. Overall RoB high for the remaining 19 models. Analysis and outcome domains were mostly at high RoB. <i>VAL</i> Overall RoB unclear for three validation studies. Overall RoB high for the remaining four validation studies. Analysis and outcome domains were mostly at high RoB.	C-statistics <sup>B</sup> ranged between 0.61 (interRAI PURS) and 0.90 (TNH-PUPP); O/E ratios <sup>B</sup> ranged between 0.91 (Berlowitz MDS) and 1.0 (prePURSE study tool) <i>Pooled C-statistics</i> <sup>B</sup> TNH-PUPP: 0.86 (95% CI 0.81–0.90), n=2 Fragmment scale: 0.79 (95% CI 0.77–0.82), n=1 <sup>C</sup> Berlowitz 11-item model: 0.75 (95% CI 0.74– 0.76), n=2 Berlowitz MDS model: 0.73 (95% CI 0.72– 0.74), n=2 interRAI PURS: 0.65 (95% CI 0.60–0.69), n=3 Compton: 0.81 (95% CI 0.78–0.84), n=2 <i>Pooled O/E ratios</i> <sup>B</sup> 0.99 (95% CI 0.95–1.04), n=2
	DEV/ VAL (no. studies) DEV (34); unclear (1) <sup>A</sup> DEV (9) DEV (9) DEV (3) DEV (21); VAL (7)	DEV/ VAL (no. studies)Setting of included studies; data sourcesDEV (34); unclear (1)AHAPI/CAPI n=32; SRPI n=2; detection of PI (effect on length of stay) n=1; nursing home residents n=2DEV (9)ICU n=3; operating room n=2; acute care hospital n=1; oncology department n=1; end- of-life care n=1; mobility-related disabilities n=1DEV (3)SRPI cardiovascular n=2; SRPI critical care n=1DEV (21); VAL (7)DEV General acute care hospital n=7; long-term care n=5; specific acute care (e.g. ICU) n=4; cardiovascular surgery n=2; trauma and burn centres n=1; rehabilitation units n=1; unclear n=1Prospective n=10; retrospective n=11VAL Long-term care n=3; specific acute care (e.g. ICU) n=2; general (acute care) hospital n=2	DEV/ VAL (no. studies)Setting of included studies; data sourcesModel development algorithmsDEV (34); unclear (1)^AHAPI/CAPI n=32; SRPI n=2; detection of PI (effect on length of stay) n=1; nursing home residents n=2LR n=20; RF n=18; DT n=12; SVM n=12; MLP n=9; KNN n=4; LDA n=1; other n=19DEV (9)ICU n=3; operating room n=2; acute care hospital n=1; oncology department n=1; end- of-life care n=1; mobility-related disabilities n=1DT n=5; LR n=3; SVM n=2; NN n=2; RF n=1; MTS n=1; BN n=1; gradient boosting n=1DEV (3)SRPI cardiovascular n=2; SRPI critical care n=1ANN n=1; XGBoost n=1; RF n=1DEV (21); VAL (7)DEV General acute care hospital n=7; long-term care n=5; specific acute care (e.g. ICU) n=4; cardiovascular surgery n=2; trauma and burn centres n=1; rehabilitation units n=1; unclear n=1LR n=16; cox regression n=5; ANN n=1; DT n=1; discriminant analysis n=1; C4.5 machine learning (DT induction algorithm) n=1; NS n=1VAL Long-term care n=3; specific acute care (e.g. ICU) n=2; general (acute care) hospital n=2ICT induction algorithm) n=1; NS n=1	DEV/ VAL (no. studies)Setting of included studies; data sourcesModel development algorithmsInternal validation methodDEV (34); unclear (1)^AHAPI/CAPI n=32; SRPI n=2; detection of PI (effect on length of stay) n=1; nursing home residents n=2LR n=20; RF n=18; DT n=12; SVM n=12; MLP n=9; KNN n=4; LDA n=1; other n=19CV n=10; split sample n=10; split sample n=10; split sample and CV n=8; NS=7DEV (9)ICU n=3; operating room n=2; acute care hospital n=1; oncology department n=1; end- of-life care n=1; mobility-related disabilities n=1DT n=5; LR n=3; SVM n=2; NN n=2; RF n=1; MTS n=1; BN n=1; gradient boosting n=1Split sample n=4; NS n=9DEV (3)SRPI cardiovascular n=2; SRPI critical care n=1ANN n=1; XGBoost regression n=5; ANN n=1; DT n=1; discriminant analysis n=1; c4.5 machine learning (DT induction algorithm) n=1; NS n=1Split sample n=2; NS n=1DEV (21); VAL (7)DEV General acute care hospital n=7; readiovascular surgery n=2; trauma and burn centres n=1; rehabilitation units n=1; unclear n=1LR n=16; cox regression n=5; ANN n=1; DT n=1; discriminant analysis n=1; c4.5 machine learning (DT induction algorithm) n=1; NS n=1CV n=1; tree- pruning n=1; split sampling n=2; NS n=16DEV (21); VAL (7)VL Long-term care n=3; specific acute care (e.g. ICU) n=2; general (acute care) hospital n=2LR n=16; cox regression n=5; machine learning (DT induction algorithm) n=1; NS n=1CV n=1; tree- sampling n=2; NS n=16	DEV/ VAL (no. studies)         Setting of included studies; data (no. studies)         Model development agorithms         Internal validation method         Brief description of study quality           DEV (34); unclear (1)^A         HAPI/CAPI n=32; SRPI n=2; detection of PI (effect on length of stay) n=1; nursing home residents n=2         LR n=20; RF n=18; DT n=12; SVM residents n=2         CV n=10; split sample n=10; split sample n=10; split sample n=10; split sample n=10; split sample n=4; oncology department n=1; end- disabilities n=1         No RoB assessed using PROBAST. Overall RoB high for all predictive models. All models at high RoB in analysis domain.           DEV (9)         ICU n=3; operating room n=2; acute care hospital n=1; oncology department n=1; end- disabilities n=1         DT n=5; LR n=3; SVM n=2; NN n=2; RF n=1; MTS n=1; BN n=1; gradient boosting n=1         Split sample n=4; NS n=9         RoB assessed using PROBAST. Overall RoB high for all predictive models. All models at high RoB in analysis domain.           DEV (3)         SRPI cardiovascular n=2; SRPI critical care n=1         ANN n=1; XGBoost n=1; RF n=1         Split sample n=2; NS n=1         No RoB assessed using PROBAST. Overall RoB unclear for two models. Analysis and outcome domains were mostly at high RoB. N=1         DEV Overall RoB unclear for two models. Analysis and outcome domains were mostly at high RoB. VAL Long-term care n=3; specific acute care (e.g. ICU) n=2; general (acute care (

217 Table 2. Results of reviews reporting model development and validation

Review author (publication year)	DEV/ VAL (no. studies)	Setting of included studies; data sources	Model development algorithms	Internal validation method	Brief description of study quality	Summary of model performance results
		Prospective n=3; retrospective n=4				Berlowitz MDS 0.94 (95% CI 0.88–1.01), n=2
Zhou <sup>53</sup> (2022)	DEV (22)	SRPI n=3; ICU n=11; hospitalised n=6; rehabilitation centre n=1; hospice n=1	LR n=15; RF n=10; DT n=9; SVM; n=9; ANN n=8; BN n=3; XGBoost n=3; GB	CV n=12; NS n=10	RoB assessed using PROBAST. Overall RoB unclear for five studies. Overall RoB high for 15 models. RoB not assessed in two	F1 score ranged between 0.02 (ML Nakagami) and 0.99 (ML Song [2]); AUC ranged between 0.78 (ML Delparte) and 0.99 (ML Song [2]); sensitivity tanged between 0.08 (ML Cai) and
		EHR n=18; Medical Information Mart for Intensive care III database n=4	n=2; AdaBoost n=1; CANTRIP n=1; LSTM n=1; EN n=1; KNN n=1; MTS n=1; NB n=1		studies due to use of unstructured data.	0.99 (ML Song [2]); specificity ranged between 0.63 (ML Delparte) and 1 (ML Cai)

218 <sup>A</sup>Appears to be a model validation study but the review only included model development studies.

<sup>B</sup>Values from fixed-effects meta-analyses, pooling development and external validation study estimates together.

220 <sup>c</sup> One data source but included two C-statistic values (one for model development and one for internal validation) that were subsequently pooled.

AUC – area under curve; ANN – artificial neural network; BN – Bayesian network; CAPI – community-acquired pressure injury; CANTRIP - reCurrent Additive Network for Temporal RIsk

222 Prediction; CV – cross-validation; DEV – development; DT – decision tree; EHRs – electronic health records; EN – elastic net; GB – gradient boosting; HAPI – hospital-acquired pressure injury;

223 ICU – intensive care unit; KNN – k-nearest neighbours; LDA – linear discriminant analysis; LSTM – long short-term memory; LR – logistic regression; ML – machine learning; MLP – multilayer

224 perception; MTS – Mahalanobis-Taguchi system; N/A – not applicable; NB – naïve Bayes; NN – neural network; O/E – observed vs expected; PI – pressure injury; PROBAST – Prediction model

225 Risk of Bias ASsessment Tool; RF – random forest; RoB – risk of bias; SRPI – surgery-related pressure injury; SVM – support vector machine; VAL – validation.

#### Findings 226

- 227 Of the 28 reviews, 23 reviews focused on the clinical utility of prediction tools provided no details
- 228 about the development or validation of included models (see Appendix 5), and gave only limited
- 229 detail about setting and study design. These reviews included a total of 63 different prediction tools,
- 230 predominantly derived by clinical experts, as opposed to empirically-derived models. The most
- 231 commonly included tools were the Braden (included in 20 reviews), Waterlow (n=14 reviews),
- 232 Norton (n=11 reviews), and Cubbin and Jackson scales (n=8 reviews).
- 233 The five systematic reviews that reported detailed information about model development and
- validation included 62 prediction models, 40 of which were unique to these five reviews (between 234
- one<sup>37</sup> and 20<sup>52</sup> unique models were included per review) (Table 2). Between three<sup>51</sup> and 35<sup>36</sup> model 235
- 236 development studies were included; one review<sup>52</sup> also included 7 external validation studies.
- 237 Electronic health records (EHRs) were used for model development in all studies in one review<sup>37</sup> and
- in 18 of 22 models (82%) in a second review.<sup>53</sup> One review<sup>52</sup> reported the use of prospectively or 238
- 239 retrospectively collected data (n=10 studies and n=11 studies, respectively). No review included
- 240 information about the thresholds used define whether a patient is at risk of developing PIs. Four
- 241 reviews included detail about the predictors included in each model.
- The largest review<sup>36</sup> reported that logistic regression was the most commonly reported modelling 242
- 243 approach (20/35 models), followed by random forest (n=18), decision tree (n=12) and support vector
- machine (n=12) approaches. Logistic regression was also the most frequently used in two other 244
- reviews (16/21<sup>52</sup> and 15/22<sup>53</sup>). Primary studies frequently compared the use of different ML methods 245
- 246 using the same datasets, such that 'other' ML methods were reported with little to no further detail
- 247 (e.g. 19 studies in the review by Dweekat and colleagues<sup>36</sup>).
- 248 Approaches to internal validation were not well reported in the primary studies. One review<sup>52</sup> found 249 no information on internal validation for 76% (16/21) of studies; with re-sampling reported in two
- 250 and tree-pruning, cross-validation and split sample reported in one study each. Another<sup>36</sup> reported
- 251 no information about internal validation for 20% of studies (7/35) and the use of cross-validation
- 252 (n=10), split sample (n=10) techniques, or both (n=8) for the remainder. Cross-validation was used in
- 253 more than half (12/22) of studies in another.<sup>53</sup> Only one review reported any detail about methods
- for selection of model predictors<sup>52</sup>: 29% (6/21) selected predictors by univariate analysis prior to 254
- 255 modelling and 9 used stepwise selection for final model predictors; 11 (52%) clearly reported 256
- candidate predictors, and all 21 clearly reported final model predictors. The same review<sup>52</sup> reported 257
- 15 models (71%) with no information about missing data, and only two using imputation techniques.
- Model performance measures were reported by three reviews<sup>37 52 53</sup>, all of which noted considerable 258
- 259 variation in reported metrics and model performance including C-statistics (0.71 to 0.89 in 10
- 260 studies<sup>53</sup>), F1 score (0.02 to 0.99 in 9 studies<sup>53</sup>), G-means (0.628 to 0.822 in four studies<sup>37</sup>), and
- observed versus expected ratios (0.97 to 1 in 3 studies<sup>52</sup>). Two reviews reported accuracy metrics 261
- 262 associated with included models: sensitivity ranged between 0.48 and 0.85 and specificity between 263 0.70 and 0.99 for 7 models in one review,<sup>37</sup> compared to sensitivity 0.08 to 0.99 (for 19 studies<sup>52</sup>) and
- specificity 0.63 to 1.00 (for 18 studies<sup>52</sup>) in another. AUC ranged between 0.78 and 0.99 for 16 264
- 265 studies<sup>52</sup>.
- Shi and colleagues<sup>52</sup> included 7 external validations using data from long-term care (n=3) or acute 266
- hospital care (n=4) settings. All were judged to be at unclear (n=3) or high (n=4) risk of bias using 267
- PROBAST. Model performance metrics for five models (TNH-PUPP<sup>69</sup>, Berlowitz 11-item model<sup>70</sup>, 268
- Berlowitz MDS adjustment model<sup>71</sup>, interRAI PURS<sup>72</sup>, Compton ICU model<sup>73</sup>) included C-statistics 269
- 270 between 0.61 and 0.9 and reported observed versus expected ratios were between 0.91 and 0.97.

- 271 The review also reported external validation studies for the 'SS scale' and the prePURSE study tool,
- 272 but no model performance metrics were given. A meta-analysis of C-statistics and O/E ratios was
- 273 performed, including values from both development and external validation cohorts (Table 2).
- 274 Parameters related to model development were not consistently reported: C-statistics ranged
- between 0.71 and 0.89 (n = 10 studies); observed versus expected ratios ranged between 0.97 and 1
- 276 (n=3 studies). For more detailed information about individual models, including predictors, specific
- 277 model performance metrics and sample sizes (Appendix 5).

#### 278 Included tools and predictors

A total of 116 risk prediction tools were identified (Table 3); 103 were identified from the 28 included

- 280 systematic reviews and 13 were identified from screening the reference lists of the 'non-systematic'
- reviews that were considered during full text assessment. Full details obtained at review-level are
   reported in Appendix 5 Table S4.
- Tools were categorised as having been developed with (52/116, 45%) or without (64, 55%) the use of
- 284 ML methods. Prospectively collected data was used for model development for 19% of tools
- 285 (22/116), retrospectively collected data for 40% (46/116), including 18 ML-based models using EHRs,
- or was not reported (48/116). Information about the study populations was poorly reported,
- 287 however study setting was reported for 102 prediction tools. Thirty-four tools were reported to have
- been developed in hospital inpatients, and 20 were developed in long-term care settings,
- rehabilitation units or nursing homes or hospices. Where reported (n=92), sample sizes ranged from
- 15<sup>74</sup> to 1,252,313.<sup>75-82</sup> The approach to internal validation used for the prediction tools (e.g. cross-
- validation versus split sample) was not reported at review-level for almost three quarters of tools(81/116, 70%).
- 293 We could extract information about the predictors for only 53 of the 116 tools (Table 4 and Appendix
- 5). The most frequently included predictor was mobility (27/53, 51%), followed by pre-disposing
- diseases/conditions (26/53, 49%), medical treatment/care received (22/53, 42%) and continence
- 296 (22/53, 42%). Tools often (23/53, 45%) included multiple pre-existing conditions or comorbidities and
- multiple types of treatment or medication as predictors. Other common predictors include age,
   nutrition, mental status, activity, skin conditions and laboratory values (34% to 40% of models).
- 299 Seven tools incorporated scores from other established risk prediction scales as a predictor, with six
- 300 including Braden scores and one including the Norton score.
- 301 Only one review<sup>52</sup> reported the presentation format of included tools, coded as 'score system'
- 302 (n=11), 'formula equation' (n=3), 'nomogram scale' (n=2), or 'not reported' (n=6).
- 303

304

305 Table 3. Summary of tool characteristics, extracted at review	v-level
---	---------

Tool characteristics	ML-based models (N=52, 45%)	Non-ML tools (N=64, 55%)	Total (N=116)
No. of included reviews <sup>A</sup> considered in			
0	0 (0)	13 (20)	13 (11)
1	30 (58)	23 (36)	53 (46)
2	8 (15)	9 (14)	17 (15)
>2	14 (27)	19 (30)	33 (28)
Development study details			
Median (range) year of publication	2020 (2000 – 2022)	1998 (1962 – 2015)	2006 (1962 – 2022)
Source of data			
Prospective	4 (8)	18 (28)	22 (19)
Retrospective	36 (69)	10 (16)	46 (40)
NS	12 (23)	36 (56)	48 (41)
Setting			
Hospital	13 (25)	11 (17)	24 (21)
Long-term care (incl. end-of-life and rehab)	6 (12)	14 (22)	20 (17)
Acute care (incl. surgical and ICU)	28 (54)	24 (38)	52 (45)
Mixed settings	1 (2)	1 (2)	2 (2)
Other	2 (4)	2 (3)	4 (3)
NS	2 (4)	12 (19)	14 (12)
Study population age			
Adults	31 (60)	34 (53)	65 (56)
Any	5 (10)	3 (5)	8 (7)
NS	16 (31)	27 (42)	43 (37)
Baseline condition			
PIs at baseline	1 (2)	0 (0)	1 (1)
No PIs at baseline	11 (21)	19 (30)	30 (26)
NS	40 (77)	45 (70)	85 (73)
Development methods			
Development method/algorithm <sup>B</sup>			
ML algorithms	52 (100)	0 (0)	52 (45)
Logistic regression	35 (67)	15 (23) <sup>c</sup>	50 (43)
Cox regression	0 (0)	5 (8)	5 (4)
Clinical expertise	0 (0)	2 (3)	2 (2)
NS	0 (0)	44 (69) <sup>D</sup>	44 (38)
Internal validation method			
Cross-validation	21 (40)	3 (5) <sup>G</sup>	24 (21)
Data splitting	11 (21)	0 (0)	11 (9)
Not done / NS	20 (38) *	61 (95)	81 (70)
Median (range) no. of final predictors <sup>E</sup>	6 (3 – 23)	8 (2 – 15)	7 (2 – 23)
Study cohort			
Median (range) total sample size	3000 (27 – 1252313)	320 (15 – 31150)	686 (15 – 1252313)
Median (range) number of events	206 (8 – 86410)	51 (9 – 1350)	94 (8 – 86410)
Median (range) proportion of events	10.65% (0.42% –	14.84% (1.18% –	14.40% (0.42% –
(% of sample size)	80.00%)	46.67%)	80.00%)

<sup>306</sup> 

<sup>A</sup> the 28 included systematic reviews; <sup>B</sup> tools use multiple methods, therefore total number not equal to N (100%); <sup>C</sup> one 307 study also used discriminant analysis for model development; <sup>D</sup> many seemed to use clinical expertise, but development

methods were not clearly reported; <sup>E</sup> counting of final predictors may vary between models: some authors may count 308 309 individual factors, while others consider domains or subscales; <sup>F</sup> one review<sup>36</sup> implies 5 models did not implement internal

310 validation; <sup>G</sup> 'resampling' (not described further) was used for the development of 2 models; ML – machine learning; NS –

311 not stated; ICU – intensive care unit; PI – pressure injury.

312

Dradictor catagony	No. of tools
Predictor category	predictor appears in
Mobility	27 (51)
Pre-disposing conditions	26 (49)
Continence	22 (42)
Receiving medical treatment/care	22 (42)
Age	21 (40)
Mental Status	20 (38)
Nutrition	20 (38)
Activity	19 (36)
Laboratory values	18 (34)
Skin	18 (34)
General Health	16 (30)
Body	13 (25)
Gender	11 (21)
Surgery duration	7 (13)
Ability to ambulate	6 (11)
Braden score	6 (11)
Pressure injury	6 (11)
Friction, shear, pressure	5 (9)
Medical unit, ward, visit	5 (9)
Length of stay	4 (8)
Hygiene	3 (6)
Ethnicity	2 (4)
Pain	2 (4)
Smoking	2 (4)
'Special' (not explained)	2 (4)
Isolation	1 (2)
Norton score	1 (2)

Table 4. Predictor categories and frequency (%) of inclusion in N=53 models.

Figures are given as count (% out of 53 tools with information on predictors). Note that multiple predictors may fall within

315 the same predictor category. For instance, the category 'skin' may encompass both 'skin moisture' and 'skin integrity', with 316 the frequency count reflecting the entire predictor category rather than individual predictors.

## 317 DISCUSSION

318 This umbrella review summarises data from 28 eligible systematic reviews of PI risk prediction tools.

319 Quality assessment using an adaptation of AMSTAR-2 revealed that most reviews were conducted to

a relatively poor standard. Critical flaws were identified, including inadequate or absent reporting of

- protocols (23/28, 82%), inappropriate meta-analysis methods (11/15, 73%) and lack of consideration
- for risk of bias judgements when discussing review results (14/28, 50%). Despite the large number of
- risk prediction models identified, only five reviews focused on the development and validation of
- 324 predominantly ML-based prediction models. The remaining reviews aimed to summarise evidence
- for the accuracy (sensitivity and specificity) or effectiveness of identified models. For many (44/64,
- 326 69%) prediction tools that were developed without the use of ML, we were not able to determine
- whether reliable and robust statistical methods were used or whether models were essentially risk
   assessment tools developed based on expert knowledge. For over half (63/116, 54%) of the
- identified tools, predictors included in the final models were not reported. Details of study
- 330 populations and settings were also lacking. It was not always clear from the reviews whether the
- 331 poor reporting occurred at review level or in the original primary study publications.
- 332 A recent systematic review of risk of bias in machine learning developed prediction models found
- that most models are of poor methodological quality and are at high risk of bias.<sup>23</sup> In our set of
- reviews, of the three reviews that conducted a risk of bias assessment using the PROBAST tool, all
- models were found to be at high or unclear risk of bias.<sup>52</sup>

- 336 Where the method of internal validation was reported, split-sample and cross-validation were the
- most commonly used techniques, however, detail was limited, and it was not possible to determine
- 338 whether appropriate methods had been used. Although split-sample approaches have been favoured
- 339 for model validation, more recent empirical work suggests that bootstrap-based optimism
- 340 correction<sup>83</sup> or cross-validation<sup>84</sup> are preferred approaches. None of the included reviews reported
- the use of optimism correction approaches.

342 Model development algorithms included logistic regression, decision trees and random forests, with

- a vast number of ML-based models having been developed in the last five years. In contrast to
  logistic regression approaches, decision trees and random forests while providing valuable risk
  classification, may not give a proper risk probability. Instead, they commonly categorise patients into
  binary 'at risk' or 'not at risk' groups. Although the risk probabilities generated in logistic regression
  prediction models can be useful for clinical decision making, it was not possible to derive any
  information about thresholds used to define 'at risk' or 'not at risk', and for most reviews, it was
  unclear what the final model comprised of. This lack of transparency poses potential hurdles in
- unclear what the final model comprised of. This lack ofapplying these models effectively in clinical settings.
- 351 Only one review included external validations of previously developed models<sup>52</sup>, however limited 352 details of model performance were presented. External validation is necessary to ensure a model is both reproducible and generalisable<sup>85 86</sup>, bringing the usefulness of the models included in these 353 354 reviews into question. The PROGRESS framework suggests that multiple external validation studies should be conducted using independent datasets from different locations.<sup>15</sup> In the only review that 355 included model validation studies<sup>52</sup>, it is unclear whether these studies were conducted in different 356 locations, and all were conducted in the same setting. PROGRESS also suggests that external 357 358 validations are carried out in a variety of relevant settings. Four out of eight validations were described as using 'temporal' data, which suggests that the validation population is largely the same 359 360 as the development population but with use of data from different timeframes. This approach has 361 been described as 'between' internal and external validation, further emphasising the need for well-362 designed external validation studies.<sup>85</sup> Furthermore, none of the eight external validations reported model recalibration. Recent evidence suggests focus should be placed on large, well-designed 363 external validation studies to validate and improve promising models (using recalibration and 364 updating<sup>87</sup>), rather than developing a multitude of new ones.<sup>18 15</sup> Model validation and recalibration 365 should be a continuous process, and this is something that future research should address. Following 366 external validation, the PROGRESS framework<sup>15</sup> suggests that effectiveness studies should be 367 conducted following external validation to assess the effect of the model on decision making, patient 368 369 outcomes and costs.
- 370 Despite the advances in methods for developing risk prediction models, scales developed using 371 clinical expertise such as the Braden Scale, Norton Scale, Waterlow Score and Cubbin-Jackson Scale are extensively discussed in numerous clinical practice guidelines for patient risk assessment, and are 372 commonly used in clinical practice.<sup>6 88</sup> Although guidelines recognise their low accuracy, they are still 373 374 acknowledged, while other risk prediction models are not even considered. This may be due to the 375 availability of at least some clinical trials evaluating the clinical utility of scales.<sup>39</sup> Some scales, such as 376 the Braden scale, are so widely used that they have become an integral component of risk 377 assessment for PI in clinical practice, and have even been incorporated into EHRs. Their widespread 378 use may impede the progress towards development, validation and evaluation of more accurate and 379 innovative risk prediction models. Striking a balance between tradition and embracing advancements 380 is crucial for effective implementation in healthcare settings and improving patient outcomes.

#### 381 Other existing evidence

- 382 We are aware of one additional systematic review of ML prediction models for PIs published after
- 383 our search was conducted.<sup>89</sup> Pei and colleagues included 18 models, all of which were already
- included in our list of identified models. The aim of the review was to assess risk factors related to
- 385 HAPIs, rather than assess tools to predict PIs and only ML-based models were included. A meta-
- analysis was conducted by pooling prognostic accuracy measures across all models that provided 2x2
- data (n=14 models). The pooled AUC across the 14 models was 0.94, pooled sensitivity was 0.79
   (95% CI 0.78–0.80) and pooled specificity was 0.87 (95% CI 0.88–0.87).<sup>89</sup> A meta-regression was
- (95% CI 0.78–0.80) and pooled specificity was 0.87 (95% CI 0.88–0.87).<sup>89</sup> A meta-regression was
   conducted to investigate whether these values differed by machine learning algorithm; no difference
- 390 based on algorithm was found. Review authors found 16/18 studies at high risk of bias based on
- 391 PROBAST. We had low confidence in the review itself, through applying our adapted AMSTAR-2
- 392 criteria; one critical flaw was their use of inappropriate meta-analysis methods (not using a
- 393 hierarchical model for pooling sensitivity and specificity).

#### **394** Strengths and limitations

- 395 Our umbrella reviews were conducted to a high standard, following Cochrane guidance<sup>40</sup>, and with a
- highly sensitive search strategy designed by an experienced information specialist. Although we
- 397 excluded non-English publications due to time and resource constraints, where possible these
- 398 publications were used to identify additional eligible risk prediction models. To some extent our
- review is limited by the use of AMSTAR-2 for quality assessment of included reviews. AMSTAR-2 was
- 400 not designed for assessment of diagnostic or prognostic studies and, although we made some
- 401 adaptations, many of the existing and amended criteria relate to the quality of reporting of the
- 402 reviews as opposed to methodological quality. There is scope for further work to establish criteria for
- 403 assessing systematic reviews of prediction models.
- 404 The main limitation, however, was the lack of detail about risk prediction models and risk prediction
- 405 model performance that could be determined from the included systematic reviews. To be as
- 406 comprehensive as possible in model identification, we were relatively generous in our definition of
- 407 'systematic', and this may have contributed to the often poor level of detail provided by included
- 408 reviews. It is likely, however, that reporting was poor in many of the primary studies contributing to
- 409 these reviews. Excluding the ML-based models, more than half of available risk prediction scales or
- 410 tools were published prior to the year 2000. The fact that the original versions of reporting
- guidelines for diagnostic accuracy studies<sup>90</sup> and risk prediction models<sup>91</sup> were not published until
- 412 2003 and 2015 respectively, is likely to have contributed to poor reporting. In contrast, the ML-based
- models were published between 2000 and 2022, with a median year of 2020. Reporting guidelines
   for development and validation of ML-based models are more recent<sup>92</sup> or still in development<sup>93</sup>, but
- 415 aim to improve the reporting standards and understanding of evolving ML technologies in
- 416 healthcare.

## 417 CONCLUSIONS

- There is a very large body of evidence reporting various risk prediction scales, tool and models for PI
- 419 which has been summarised across multiple systematic reviews of varying methodological quality.
- 420 Only five systematic reviews reported the development and validation of models to predict risk of
- 421 PIs. It seems that for the most part, available models do not meet current standards for the
- 422 development or reporting of risk prediction models. Furthermore, most available models, including
- 423 ML-based models have not been validated beyond the original population in which they were
- 424 developed. Identification of the optimal risk prediction model for PI from those currently available
- 425 would require a high-quality systematic review of the primary literature, ideally limited to studies

- 426 conducted to a high methodological standard. It is evident from our findings that there is still a lack
- 427 of consensus on the optimal risk prediction model for PI, highlighting the need for more standardised
- 428 and rigorous approaches in future research.

429

## 430 Acknowledgements

We would like to thank Mrs. Rosie Boodell (University of Birmingham, UK) for her help in acquiringthe publications necessary to complete this piece of work.

# 433 Author Contributions

- 434 **Conceptualisation:** Bethany Hillier, Katie Scandrett, April Coombe, Tina Hernandez-Boussard, Ewout
- 435 Steyerberg, Yemisi Takwoingi, Vladica Velickovic, Jacqueline Dinnes
- 436 Data curation: Bethany Hillier, Katie Scandrett, April Coombe, Jacqueline Dinnes
- 437 Formal analysis: Bethany Hillier, Katie Scandrett, Jacqueline Dinnes
- 438 Funding acquisition: Yemisi Takwoingi, Vladica Velickovic, Jacqueline Dinnes
- 439 Investigation: Bethany Hillier, Katie Scandrett, April Coombe, Yemisi Takwoingi, Jacqueline Dinnes
- 440 **Methodology:** Bethany Hillier, Katie Scandrett, April Coombe, Tina Hernandez-Boussard, Ewout
- 441 Steyerberg, Yemisi Takwoingi, Vladica Velickovic, Jacqueline Dinnes
- 442 Project administration: Bethany Hillier, Yemisi Takwoingi, Jacqueline Dinnes
- 443 Resources: Bethany Hillier, Katie Scandrett
- 444 Supervision: Yemisi Takwoingi, Jacqueline Dinnes
- 445 Writing original draft: Bethany Hillier, Katie Scandrett, April Coombe, Jacqueline Dinnes
- 446 Writing review & editing: Bethany Hillier, Katie Scandrett, April Coombe, Tina Hernandez-Boussard,
- 447 Ewout Steyerberg, Yemisi Takwoingi, Vladica Velickovic, Jacqueline Dinnes

## 448 Funding

- 449 This work was commissioned and supported by Paul Hartmann AG (Heidenheim, Germany). The
- 450 contract with the University of Birmingham was agreed on the legal understanding that the authors
- 451 had the freedom to publish results regardless of the findings.
- 452 YT, JD, BH, KS and AC are funded by the National Institute for Health and Care Research (NIHR)
- 453 Birmingham Biomedical Research Centre (BRC). This paper presents independent research supported
- 454 by the NIHR Birmingham BRC at the University Hospitals Birmingham NHS Foundation Trust and the
- 455 University of Birmingham. The views expressed are those of the authors and not necessarily those of
- 456 the NIHR or the Department of Health and Social Care.

## 457 Conflicting Interests

- 458 The authors of this manuscript have the following competing interests: VV is an employee of Paul
- 459 Hartmann AG; ES and THB received consultancy fees from Paul Hartmann AG. All other authors
- 460 received no personal funding or personal compensation from Paul Hartmann AG and have declared
- that no competing interests exist.

# References

462 1. Li Z, Lin F, Thalib L, et al. Global prevalence and incidence of pressure injuries in hospitalised adult 463 patients: A systematic review and meta-analysis. International Journal of Nursing Studies 464 2020;105:103-546. doi: 10.1016/j.ijnurstu.2020.103546 2. Padula WV, Delarmente BA. The national cost of hospital-acquired pressure injuries in the United 465 466 States. Int Wound J 2019;16(3):634-40. doi: 10.1111/iwj.13071 [published Online First: 467 2019/01/28] 468 3. Theisen S, Drabik A, Stock S. Pressure ulcers in older hospitalised patients and its impact on length 469 of stay: a retrospective observational study. J Clin Nurs 2012;21(3-4):380-7. doi: 470 10.1111/j.1365-2702.2011.03915.x [published Online First: 2011/12/09] 471 4. Sullivan N, Schoelles K. Preventing In-Facility Pressure Ulcers as a Patient Safety Strategy. Annals of 472 Internal Medicine 2013;158(5.2):410-16. doi: 10.7326/0003-4819-158-5-201303051-00008 473 5. Institute for Quality and Efficiency in Health Care (IQWiG). Preventing pressure ulcers. Cologne, 474 Germany 2006 [updated 2018 Nov 15. Available from: 475 https://www.ncbi.nlm.nih.gov/books/NBK326430/?report=classic accessed Feb 2023]. 476 6. Haesler E. European Pressure Ulcer Advisory Panel, National Pressure Injury Advisory Panel and 477 Pan Pacific Pressure Injury Alliance. Prevention and Treatment of Pressure Ulcers/Injuries: 478 Clinical Practice Guideline. 2019 [Available from: https://internationalguideline.com/2019 479 accessed Feb 2023]. 480 7. Walker RM, Gillespie BM, McInnes E, et al. Prevention and treatment of pressure injuries: A meta-481 synthesis of Cochrane Reviews. Journal of Tissue Viability 2020;29(4):227-43. doi: 482 10.1016/j.jtv.2020.05.004 483 8. Shi C, Dumville JC, Cullum N, et al. Beds, overlays and mattresses for preventing and treating 484 pressure ulcers: an overview of Cochrane Reviews and network meta-analysis. Cochrane 485 Database Syst Rev 2021;8(8):Cd013761. doi: 10.1002/14651858.CD013761.pub2 [published 486 Online First: 2021/08/16] 487 9. Russo CA, Steiner C, Spector W. Hospitalizations Related to Pressure Ulcers, 2006. HCUP Statistical 488 Brief: Agency for Healthcare Research and Quality, Rockville, MD. 2008. 489 10. Braden B, Bergstrom N. A Conceptual Schema for the Study of the Etiology of Pressure Sores. 490 Rehabilitation Nursing 1987;12(1):8-16. doi: 10.1002/j.2048-7940.1987.tb00541.x 491 11. Bergstrom N, Braden BJ, Laguzza A, et al. The Braden Scale for Predicting Pressure Sore Risk. Nurs 492 Res 1987;36(4):205-10. 493 12. Norton D. Geriatric nursing problems. Int Nurs Rev 1962;9:39-41. 494 13. Waterlow J. Pressure sores: a risk assessment card. Nursing Times 1985;81:49-55. 495 14. Steyerberg EW, Harrell FE, Jr. Prediction models need appropriate internal, internal-external, and 496 external validation. J Clin Epidemiol 2016;69:245-7. doi: 10.1016/j.jclinepi.2015.04.005 497 [published Online First: 2015/04/18] 498 15. Steyerberg EW, Moons KGM, van der Windt DA, et al. Prognosis Research Strategy (PROGRESS) 3: 499 Prognostic Model Research. PLOS Medicine 2013;10(2):e1001381. doi: 500 10.1371/journal.pmed.1001381 501 16. Siontis GCM, Tzoulaki I, Castaldi PJ, et al. External validation of new risk prediction models is 502 infrequent and reveals worse prognostic discrimination. Journal of Clinical Epidemiology 503 2015;68(1):25-34. doi: 10.1016/j.jclinepi.2014.09.007 504 17. Bouwmeester W, Zuithoff NPA, Mallett S, et al. Reporting and Methods in Clinical Prediction 505 Research: A Systematic Review. PLOS Medicine 2012;9(5):e1001221. doi: 506 10.1371/journal.pmed.1001221 507 18. Van Calster B, Steyerberg EW, Wynants L, et al. There is no such thing as a validated prediction 508 model. BMC Medicine 2023;21(1):70. doi: 10.1186/s12916-023-02779-w 19. Wynants L, Calster BV, Collins GS, et al. Prediction models for diagnosis and prognosis of covid-509 510 19: systematic review and critical appraisal. BMJ 2020;369:m1328. doi: 10.1136/bmj.m1328

511 20. Ma J, Dhiman P, Qi C, et al. Poor handling of continuous predictors in clinical prediction models 512 using logistic regression: a systematic review. J Clin Epidemiol 2023;161:140-51. doi: 513 10.1016/j.jclinepi.2023.07.017 [published Online First: 2023/08/02] 514 21. Dhiman P, Ma J, Qi C, et al. Sample size requirements are not being considered in studies 515 developing prediction models for binary outcomes: a systematic review. BMC Medical 516 Research Methodology 2023;23(1):188. doi: 10.1186/s12874-023-02008-1 517 22. Moriarty AS, Meader N, Snell KIE, et al. Predicting relapse or recurrence of depression: systematic 518 review of prognostic models. Br J Psychiatry 2022;221(2):448-58. doi: 10.1192/bjp.2021.218 519 23. Andaur Navarro CL, Damen JAA, Takada T, et al. Risk of bias in studies on prediction models 520 developed using supervised machine learning techniques: systematic review. BMJ 521 2021;375:n2281. doi: 10.1136/bmj.n2281 522 24. Christodoulou E, Ma J, Collins GS, et al. A systematic review shows no performance benefit of 523 machine learning over logistic regression for clinical prediction models. J Clin Epidemiol 524 2019;110:12-22. doi: 10.1016/j.jclinepi.2019.02.004 [published Online First: 20190211] 525 25. Debray TPA, Damen JAAG, Snell KIE, et al. A guide to systematic review and meta-analysis of 526 prediction model performance. BMJ 2017;356:i6460. doi: 10.1136/bmj.i6460 527 26. Riley RD, van der Windt D, Croft P, et al. Prognosis research in healthcare: concepts, methods, and 528 impact: Oxford University Press 2019. 529 27. Snell KIE, Levis B, Damen JAA, et al. Transparent reporting of multivariable prediction models for 530 individual prognosis or diagnosis: checklist for systematic reviews and meta-analyses 531 (TRIPOD-SRMA). BMJ 2023;381:e073538. doi: 10.1136/bmj-2022-073538 532 28. Wolff RF, Moons KGM, Riley RD, et al. PROBAST: A Tool to Assess the Risk of Bias and Applicability 533 of Prediction Model Studies. Annals of Internal Medicine 2019;170(1):51-58. doi: 534 10.7326/M18-1376 535 29. Chen HL, Shen WQ, Liu P. A Meta-analysis to Evaluate the Predictive Validity of the Braden Scale 536 for Pressure Ulcer Risk Assessment in Long-term Care. Ostomy/wound management 537 2016;62(9):20-8. 538 30. Baris N, Karabacak BG, Alpar SE. The Use of the Braden Scale in Assessing Pressure Ulcers in 539 Turkey: A Systematic Review. Advances in skin & wound care 2015;28:349-57. doi: 540 10.1097/01.ASW.0000465299.99194.e6 541 31. He W, Liu P, Chen HL. The Braden Scale cannot be used alone for assessing pressure ulcer risk in 542 surgical patients: a meta-analysis. Ostomy/wound management 2012;58:34-40. 543 32. Huang C, Ma Y, Wang C, et al. Predictive validity of the braden scale for pressure injury risk 544 assessment in adults: A systematic review and meta-analysis. Nursing open 2021;8:2194-207. 545 doi: 10.1002/nop2.792 546 33. Park SH, Choi YK, Kang CB. Predictive validity of the Braden Scale for pressure ulcer risk in 547 hospitalized patients. Journal of Tissue Viability 2015;24:102-13. doi: 548 10.1016/j.jtv.2015.05.001 34. Wei M, Wu L, Chen Y, et al. Predictive Validity of the Braden Scale for Pressure Ulcer Risk in 549 550 Critical Care: A Meta-Analysis. Nursing in critical care 2020;25:165-70. doi: 551 10.1111/nicc.12500 552 35. Wilchesky M, Lungu O. Predictive and concurrent validity of the Braden scale in long-term care: A 553 meta-analysis. Wound Repair and Regeneration 2015;23:44-56. doi: 10.1111/wrr.12261 554 36. Dweekat OY, Lam SS, McGrath L. Machine Learning Techniques, Applications, and Potential Future 555 Opportunities in Pressure Injuries (Bedsores) Management: A Systematic Review. International journal of environmental research and public health 2023;20(1) doi: 556 557 10.3390/ijerph20010796 37. Jiang M, Ma Y, Guo S, et al. Using Machine Learning Technologies in Pressure Injury Management: 558 559 Systematic Review. JMIR Medical Informatics 2021;9(3):e25704. doi: 10.2196/25704

- 38. Qu C, Luo W, Zeng Z, et al. The predictive effect of different machine learning algorithms for
   pressure injuries in hospitalized patients: A network meta-analyses. *Heliyon* 2022;8(11):e11361. doi: 10.1016/j.heliyon.2022.e11361
- 39. Hillier B, Scandrett K, Coombe A, et al. Accuracy and clinical effectiveness of risk prediction tools
   for pressure injury occurrence: An umbrella review (pre-print). *MedRxiv* 2024 doi: TBC
   (UPDATE ME)
- 40. Pollock M, Fernandes RM BL, Pieper D, Hartling L, Chapter V: Overviews of Reviews. In: Higgins
  JPT TJ, Chandler J, Cumpston M, Li T, Page MJ, Welch VA ed. Cochrane Handbook for
  Systematic Reviews of Interventions version 63 (updated February 2022). Available from
  www.training.cochrane.org/handbook: Cochrane 2022.
- 41. Moher D, Liberati A, Tetzlaff J, et al. Preferred Reporting Items for Systematic Reviews and Meta Analyses: The PRISMA Statement. *PLOS Medicine* 2009;6(7):e1000097. doi:
   10.1371/journal.pmed.1000097
- 42. Ingui BJ, Rogers MA. Searching for clinical prediction rules in MEDLINE. *J Am Med Inform Assoc* 2001;8(4):391-7. doi: 10.1136/jamia.2001.0080391 [published Online First: 2001/06/22]
- 43. Wilczynski NL, Haynes RB. Optimal Search Strategies for Detecting Clinically Sound Prognostic
   Studies in EMBASE: An Analytic Survey. *Journal of the American Medical Informatics Association* 2005;12(4):481-85. doi: 10.1197/jamia.M1752
- 44. Geersing G-J, Bouwmeester W, Zuithoff P, et al. Search Filters for Finding Prognostic and
   Diagnostic Prediction Studies in Medline to Enhance Systematic Reviews. *PLOS ONE* 2012;7(2):e32844. doi: 10.1371/journal.pone.0032844
- 45. NHS. Pressure ulcers: revised definition and measurement. Summary and recommendations 2018
   [Available from: <u>https://www.england.nhs.uk/wp-content/uploads/2021/09/NSTPP-</u>
   <u>summary-recommendations.pdf</u> accessed Feb 2023].
- 46. AHCPR. Pressure ulcer treatment. : Agency for Health Care Policy and Research 1994:1-25.
- 47. Harker J. Pressure ulcer classification: the Torrance system. *Journal of Wound Care* 2000;9(6):27577. doi: 10.12968/jowc.2000.9.6.26233
- 48. Moons KGM, de Groot JAH, Bouwmeester W, et al. Critical Appraisal and Data Extraction for
   Systematic Reviews of Prediction Modelling Studies: The CHARMS Checklist. *PLOS Medicine* 2014;11(10):e1001744. doi: 10.1371/journal.pmed.1001744
- 49. Cochrane. DE form example prognostic models scoping review: The Cochrane Collaboration: The
   Prognosis Methods Group; [Available from: <u>https://methods.cochrane.org/prognosis/tools</u>
   accessed Feb 2023].
- 50. Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that
   include randomised or non-randomised studies of healthcare interventions, or both. *BMJ* 2017;358:j4008. doi: 10.1136/bmj.j4008
- 596 51. Ribeiro F, Fidalgo F, Silva A, et al. Literature review of machine-learning algorithms for pressure
   597 ulcer prevention: Challenges and opportunities: MDPI 2021.
- 52. Shi C, Dumville JC, Cullum N. Evaluating the development and validation of empirically-derived
   prognostic models for pressure ulcer risk assessment: A systematic review. *International journal of nursing studies* 2019;89:88-103. doi: 10.1016/j.ijnurstu.2018.08.005
- 53. Zhou Y, Yang X, Ma S, et al. A systematic review of predictive models for hospital-acquired
   pressure injury using machine learning. *Nursing open* 2022;30 doi: 10.1002/nop2.1429
- 54. Chou R, Dana T, Bougatsos C, et al. Pressure ulcer risk assessment and prevention: a systematic
   comparative effectiveness review. *Annals of internal medicine* 2013;159(1):28-38.
- 55. García-Fernández FP, Pancorbo-Hidalgo PL, Agreda JJS. Predictive Capacity of Risk Assessment
   Scales and Clinical Judgment for Pressure Ulcers: A Meta-analysis. *Journal of Wound Ostomy & Continence Nursing* 2014;41(1):24-34. doi: 10.1097/01.WON.0000438014.90734.a2
   Pancorbo-Hidalgo PL, Garcia-Fernandez FP, Lopez-Medina IM, et al. Risk assessment scales for
- 609
   pressure ulcer prevention: a systematic review. J Adv Nurs 2006;54(1):94-110. doi:

   610
   10.1111/j.1365-2648.2006.03794.x

611 57. Park SH, Lee HS. Assessing Predictive Validity of Pressure Ulcer Risk Scales- A Systematic Review 612 and Meta-Analysis. Iranian journal of public health 2016;45(2):122-33. 613 58. Park SH, Lee YS, Kwon YM. Predictive Validity of Pressure Ulcer Risk Assessment Tools for Elderly: 614 A Meta-Analysis. Western journal of nursing research 2016;38:459-83. doi: 615 10.1177/0193945915602259 616 59. Tayyib NAH, Coyer F, Lewis P. Pressure ulcers in the adult intensive care unit: a literature review of 617 patient risk factors and risk assessment scales. Journal of Nursing Education and Practice 618 2013;3(11):28-42. 619 60. Wang N, Lv L, Yan F, et al. Biomarkers for the early detection of pressure injury: A systematic 620 review and meta-analysis. Journal of Tissue Viability 2022;31:259-67. doi: 621 10.1016/j.jtv.2022.02.005 622 61. Zhang Y, Zhuang Y, Shen J, et al. Value of pressure injury assessment scales for patients in the 623 intensive care unit: Systematic review and diagnostic test accuracy meta-analysis. Intensive & 624 critical care nursing 2021;64:103009. doi: 10.1016/j.iccn.2020.103009 625 62. Zimmermann GS, Cremasco MF, Zanei SSV, et al. Pressure injury risk prediction in critical care 626 patients: an integrative review. Texto & Contexto-Enfermagem 2018;27(3) 627 63. Gaspar S, Peralta M, Margues A, et al. Effectiveness on hospital-acquired pressure ulcers 628 prevention: a systematic review. International Wound Journal 2019;16(5):1087-102. doi: 629 10.1111/iwj.13147 630 64. Ontario HQ. Pressure ulcer prevention: an evidence-based analysis. Ontario health technology 631 assessment series 2009;9(2):1-104. 632 65. Kottner J, Dassen T, Tannen A. Inter- and intrarater reliability of the Waterlow pressure sore risk 633 scale: A systematic review. International Journal of Nursing Studies 2009;46:369-79. doi: 634 10.1016/j.ijnurstu.2008.09.010 635 66. Lovegrove J, Ven S, Miles SJ, et al. Comparison of pressure injury risk assessment outcomes using 636 a structured assessment tool versus clinical judgement: A systematic review. Journal of 637 Clinical Nursing 2021 doi: 10.1111/jocn.16154 [published Online First: 2021/12/01] 638 67. Lovegrove J, Miles S, Fulbrook P. The relationship between pressure ulcer risk assessment and 639 preventative interventions: a systematic review. Journal of wound care 2018;27(12):862-75. 640 68. Moore ZEH, Patton D. Risk assessment tools for the prevention of pressure ulcers. Cochrane Database of Systematic Reviews 2019 doi: 10.1002/14651858.CD006471.pub4 641 642 69. Page KN, Barker AL, Kamar J. Development and validation of a pressure ulcer risk assessment tool 643 for acute hospital patients. Wound Repair and Regeneration 2011;19(1):31-37. doi: 644 10.1111/j.1524-475X.2010.00647.x 645 70. Berlowitz DR, Ash AS, Brandeis GH, et al. Rating long-term care facilities on pressure ulcer 646 development: Importance of case-mix adjustment. Annals of Internal Medicine 647 1996;124(6):557-63. doi: 10.7326/0003-4819-124-6-199603150-00003 648 71. Berlowitz DR, Brandeis GH, Morris JN, et al. Deriving a risk-adjustment model for pressure ulcer 649 development using the Minimum Data Set. Journal of the American Geriatrics Society 650 2001;49(7):866-71. doi: 10.1046/j.1532-5415.2001.49175.x 651 72. Poss J, Murphy KM, Woodbury MG, et al. Development of the interRAI Pressure Ulcer Risk Scale 652 (PURS) for use in long-term care and home care settings. BMC geriatrics 2010;10:67. doi: 653 10.1186/1471-2318-10-67 73. Compton F, Hoffmann F, Hortig T, et al. Pressure ulcer predictors in ICU patients: nursing skin 654 655 assessment versus objective parameters. J Wound Care 2008;17(10):417-20, 22-4. doi: 656 10.12968/jowc.2008.17.10.31304 657 74. Lowery MT. A pressure sore risk calculator for intensive care patients: 'the Sunderland 658 experience'. Intensive Crit Care Nurs 1995;11(6):344-53. doi: 10.1016/s0964-3397(95)80452-659 8 660 75. Baldwin KM, Ziegler SM. Pressure ulcer risk following critical traumatic injury. Advances in wound 661 care : the journal for prevention and healing 1998;11(4):168-73.

- 76. Bergquist S. Subscales, subscores, or summative score: evaluating the contribution of Braden
   Scale items for predicting pressure ulcer risk in older adults receiving home health care.
- 664 Journal of wound, ostomy, and continence nursing : official publication of The Wound,
- 665Ostomy and Continence Nurses Society 2001;28(6):279-89. doi: 10.1067/mjw.2001.11901266677. Song M, Choi KS. Factors predicting development of decubitus ulcers among patients admitted667for neurological problems. The Journal of Nurses Academic Society 1991;21(1):16-26.
- 78. Halfens R, Van Achterberg T, Bal R. Validity and reliability of the Braden scale and the influence of
   other risk factors: a multi-centre prospective study. *International Journal of Nursing Studies* 2000;37(4):313-19.
- 79. Choi KS, Song MS. Test of predictive validity for the new pressure risk assessment scale. *Journal of Korean Academy of Adult Nursing* 1991;3(1):19-28.
- 80. Kwong E, Pang S, Wong T, et al. Predicting pressure ulcer risk with the modified Braden, Braden,
  and Norton scales in acute care hospitals in Mainland China. *Appl Nurs Res* 2005;18(2):122-8.
  doi: 10.1016/j.apnr.2005.01.001
- 81. Pang SM, Wong TK. Predicting pressure sore risk with the Norton, Braden, and Waterlow scales in
  a Hong Kong rehabilitation hospital. *Nursing Research* 1998;47(3):147-53.
- 82. Schue RM, Langemo DK. Pressure ulcer prevalence and incidence and a modification of the
  Braden Scale for a rehabilitation unit. *Journal of wound, ostomy, and continence nursing : official publication of The Wound, Ostomy and Continence Nurses Society* 1998;25(1):36-43.
  doi: 10.1016/s1071-5754(98)90011-0
- 83. Austin PC, Steyerberg EW. Events per variable (EPV) and the relative performance of different
  strategies for estimating the out-of-sample validity of logistic regression models. *Stat Methods Med Res* 2017;26(2):796-808. doi: 10.1177/0962280214558972 [published Online
  First: 2014/11/19]
- 84. Smith GC, Seaman SR, Wood AM, et al. Correcting for optimistic prediction in small data sets. Am
   *J Epidemiol* 2014;180(3):318-24. doi: 10.1093/aje/kwu140 [published Online First:
   2014/06/24]
- 85. Ramspek CL, Jager KJ, Dekker FW, et al. External validation of prognostic models: what, why, how,
  when and where? *Clin Kidney J* 2021;14(1):49-58. doi: 10.1093/ckj/sfaa188 [published Online
  First: 2020/11/24]
- 692 86. de Hond AAH, Shah VB, Kant IMJ, et al. Perspectives on validation of clinical predictive 693 algorithms. *npj Digital Medicine* 2023;6(1):86. doi: 10.1038/s41746-023-00832-9
- 87. Binuya MAE, Engelhardt EG, Schats W, et al. Methodological guidance for the evaluation and
   updating of clinical prediction models: a systematic review. *BMC Med Res Methodol* 2022;22(1):316. doi: 10.1186/s12874-022-01801-8 [published Online First: 2022/12/12]
- 88. Qaseem A, Mir TP, Starkey M, et al. Risk Assessment and Prevention of Pressure Ulcers: A Clinical
   Practice Guideline From the American College of Physicians. *Annals of Internal Medicine* 2015;162(5):359-69. doi: 10.7326/m14-1567
- 89. Pei J, Guo X, Tao H, et al. Machine learning-based prediction models for pressure injury: A
   systematic review and meta-analysis. *Int Wound J* 2023 doi: 10.1111/iwj.14280 [published
   Online First: 2023/06/20]
- 90. Bossuyt PM, Reitsma JB, Bruns DE, et al. STARD 2015: an updated list of essential items for
   reporting diagnostic accuracy studies. *BMJ* 2015;351:h5527. doi: 10.1136/bmj.h5527
   [published Online First: 2015/10/28]
- 91. Moons KG, Altman DG, Reitsma JB, et al. Transparent Reporting of a multivariable prediction
   model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration. *Ann Intern Med* 2015;162(1):W1-73. doi: 10.7326/m14-0698
- 92. Hernandez-Boussard T, Bozkurt S, Ioannidis JPA, et al. MINIMAR (MINimum Information for
   Medical AI Reporting): Developing reporting standards for artificial intelligence in health
   care. Journal of the American Medical Informatics Association 2020;27(12):2011-15. doi:
   10.1093/jamia/ocaa088

713 93. Collins G, Dhiman P, Logullo P, et al. TRIPOD+AI. OSF, 2023.